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Hypercholesterolemia boosts joint destruction in
chronic arthritis. An experimental model
aggravated by foam macrophage infiltration
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Abstract
Objective: The aim of this study was to determine whether hypercholesterolemia increases articular damage in a
rabbit model of chronic arthritis.
Methods: Hypercholesterolemia was induced in 18 rabbits by administrating a high-fat diet (HFD). Fifteen rabbits
were fed normal chow as controls. Chronic antigen-induced arthritis (AIA) was induced in half of the HFD and
control rabbits, previously immunized, by intra-articular injections of ovalbumin. After sacrifice, lipid and systemic
inflammation markers were analyzed in blood serum. Synovium was analyzed by Krenn score, multinucleated cell
counting, immunohistochemistry of RAM11 and CD31, and TNF-a and macrophage chemoattractant protein-1
(MCP-1) gene expression. Active bone resorption was assessed by protein expression of receptor activator of
nuclear factor kappa-B ligand (RANKL), osteoprotegerin (OPG) and quantification of cathepsin K, contact surface
and the invasive area of pannus into bone.
Results: Rabbits receiving the HFD showed higher total serum cholesterol, HDL, triglycerides and CRP levels than
rabbits fed a normal diet. Synovitis score was increased in HFD, and particularly in AIA and AIA + HFD groups. AIA
+ HFD synovium was characterized by a massive infiltration of RAM11+ cells, higher presence of multinucleated
foam cells and bigger vascularization than AIA. Cathepsin K+ osteoclasts and the contact surface of bone resorbing
pannus were also increased in rabbits with AIA + HFD compared with AIA alone. Synovial TNF-a and MCP-1 gene
expression was increased in AIA and HFD rabbits compared with healthy animals. RANKL protein expression in AIA
and AIA + HFD groups was higher compared with either HFD or normal groups.
Conclusions: This experimental model demonstrates that hypercholesterolemia increments joint tissue damage in
chronic arthritis, with foam macrophages being key players in this process.
Introduction
The increased burden of cardiovascular disease in rheu-
matoid arthritis (RA) is only explained partly by tradi-
tional cardiovascular risk factors. They seem to have
similar prevalence in RA and non-RA patients, suggesting
that other factors contribute significantly to this health
issue [1,2]. In fact, non-traditional risk factors, such as
RA disease activity/severity measures and some anti-
rheumatic drugs, have been consistently associated with
increased cardiovascular risk. Thus, RA inflammation
plays a notable role in the development of cardiovascular
disease.
Chronic synovitis is a source of inflammatory media-
tors that include cytokines, chemokines and adipokines,
such as TNF-a, macrophage chemoattractant protein-1
(MCP-1), plasminogen activator inhibitor-1, interleukin
(IL)-6 and others. In addition to the production of most
of these pro-inflammatory cytokines, there is increasing
evidence concerning the contribution of dysregulated
adipose tissue through adipokine secretion to systemic
RA inflammation [3]. Indeed, the inflammatory actions
exerted by adipokines could explain some of the associa-
tion between several rheumatic diseases and cardiovascu-
lar comorbidities [4]. A relevant role has been suggested
for leptin in immunity, not only by maintaining energy
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homeostasis but also by regulating the function of
immune cells. Specifically, leptin has been shown to pro-
mote phagocytic function and induce production of sev-
eral pro-inflammatory cytokines in macrophages and
monocytes [5]. Serum resistin levels have been shown to
be higher in patients with RA than in healthy controls
and correlate with inflammation and joint damage. In
RA, macrophages, among other immune cells, showed
co-localization with resistin [6]. An increase of leptin and
resistin (pro-atherogenic hormones) and the decrease of
adiponectin (anti-atherogenic hormone) may alter
endothelial homeostasis in RA patients [7].
Endothelial dysfunction occurs in early stages of RA
and atherosclerosis as a response to the raised expression
of chemokines and adhesion molecules, promoting the
enhancement of vessel wall permeability. These events
favor leukocyte trafficking toward the site of synovial
inflammation in arthritis [8] and/or promote infiltration
of lipids, monocytes and T-lymphocytes. Further appear-
ance of foam cells and fatty streaks within the vessel wall
originates the formation of atherosclerotic plaques [9]. In
addition, recent data showed that the vascular regenera-
tive action of endothelial progenitor cells is altered in RA
and atherosclerosis [10-13]. Therefore, the increase of
pro-inflammatory signals and the impairment of repara-
tory processes, both mechanisms shared between RA and
atherosclerosis, may contribute significantly to joint
damage in RA.
The role of hypercholesterolemia in the progression of
atherosclerosis is well established [14,15]. Severe hyperch-
olesterolemia aggravated atherosclerotic plaques instability
and aortic lesions mainly due to massive M infiltration in
our animal rabbit model of atherosclerosis associated with
chronic arthritis [16]. Macrophages (M) act as immune
innate cells, antigen presenting cells and, finally, effector
cells for joint inflammation in both acute and chronic
phases. Indeed, M contribute to the hyperplasia of the
lining layer, and are the main cells in the mononuclear
infiltration of the synovial sublining and the cartilage-pan-
nus junction, as well as, the major producers of prominent
inflammatory mediators. Activated M may also differ-
entiate into osteoclast-like cells and become involved in
bone resorption [17-20]. Because relevant pathophysiologi-
cal mechanisms occur similarly in both atherosclerosis and
chronic inflammatory states, we hypothesize that hyperch-
olesterolemia may also significantly contribute to joint
damage in chronic arthritis through the enhancement of
M aggressiveness, as suggested in early findings in our
previous study [16].
In this regard, significant research efforts have just
begun to explore the mechanisms underlying the influ-
ence of hypercholesterolemia in the development and
progression of inflammatory arthritis. During hyperlipi-
demia, adipocytes release well-known pro-inflammatory
mediators and adipokines that play relevant roles in
inflammatory arthritides [21]. A lipid-rich diet has been
shown to contribute to the switch in polarization of adi-
pose tissue M from an anti-inflammatory (M2) to a
pro-inflammatory (M1) state associated with obesity-
induced insulin resistance [22]. This change induces
systemic inflammation and potentially increases the pro-
gression of chronic arthritis. Hyperlipidemia has also
been suggested to promote the osteoclastic potential of
bone marrow cells in vivo. Indeed, the presence of lipid
oxidation products in bone marrow and an increased
osteoclast size in bones indicates a functional, but not
numeric, difference in osteoclasts as described in hyper-
lipidemic mice [23]. Furthermore, diet-induced hyperch-
olesterolemia in mice was associated with reduced bone
quality measures that resemble human bone with osteo-
porosis [24]. Thus, hypercholesterolemia may start a sys-
tematic loss of bone homeostasis.
Therefore, in this study we determine whether hyperch-
olesterolemia increases articular damage in a rabbit model
of chronic arthritis and if this effect occurs through the
activation of the synovial mononuclear phagocyte system.
Material and methods
Experimental model in rabbits
Adult male New Zealand rabbits with a body weight of
3 to 3.5 kg (Granja San Bernardo, Navarra, Spain) were
used for the experimental procedures. Animal handling
and experimentation were performed in accordance with
Spanish Regulations and the Guidelines for the Care and
Use of Laboratory Animals drawn up by the National
Institutes of Health (Bethesda, MD, USA). The experimen-
tal protocol was approved by the Institutional Ethics
Committee.
After two weeks of adaptation to our facilities, 18 rabbits
were fed ad libitum with a high-fat diet (HFD) consisting
of 1% cholesterol + 3% peanut oil (Harlan, Inc., Indianapo-
lis, IN, USA). One week later, antigen-induced arthritis
(AIA) was induced in half of these animals (n = 9; AIA +
HFD) according to a protocol previously described [16].
Briefly, animals were given two intradermal injections of
1 ml ovalbumin (OVA) (4 mg/ml; Sigma-Aldrich, St.
Louis, MO, USA) in Freund’s complete adjuvant (Difco,
Detroit, MI, USA). Five days after the second injection,
1 ml of OVA (5 mg/ml in 0.9% NaCl) was injected intra-
articularly into the knee joint on a weekly basis over the
following four weeks (Figure 1A). The other half of HFD-
fed rabbits underwent no injections (n = 9; HFD). We
simultaneously induced AIA in a group of nine rabbits
receiving standard chow. From this group, two rabbits
died for unknown reasons and the remaining rabbits went
through the whole study (n = 7; AIA). Eight additional
rabbits fed with standard chow and spared from any
experimental intervention were used as healthy controls.
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At the end of the study, rabbits were bled from their
marginal ear vein, and then euthanized with an overdose
of pentobarbital (Braun Medical SA, Barcelona, Spain) in
order to evaluate chronic damage. The synovial mem-
branes of the right knee of each rabbit were fixed in 4%
buffered paraformaldehyde and embedded in paraffin for
histological studies to be performed. The synovial mem-
branes from the left knees were immediately frozen and
used for molecular biology studies. Both femurs were
fixed, decalcified for four weeks in 10% formic acid plus
5% paraformaldehyde, and then embedded in paraffin.
Articular cartilage and subchondral bone were obtained
from both tibias for gene and protein expression studies.
Serum chemistry
Ten milliliters of blood were used for serum extraction.
Total and high-density lipoprotein (HDL) cholesterol
and triglycerides were measured by Advia®2400
Figure 1 Effect of the hyperlipemic diet and chronic antigen-induced arthritis (AIA) on serum content. A, Schematic representation of
the experimental model. B, Total cholesterol (Total Chol), high density lipoprotein (HDL) cholesterol and triglycerides levels (mg/dl) in the sera of
healthy rabbits, high-fat diet (HFD) rabbits, AIA rabbits and AIA + HFD rabbits. C, Concentration of C reactive protein (µg/ml) in the sera of
experimental rabbits. Bars show the mean and SEM (n = 7 to 9 rabbits per group). OVA, Ovalbumin.
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chemistry system (Siemens Healthcare Diagnostics,
Tarrytown, NY, USA). A specific enzyme-linked immu-
nosorbent assay kit was used to measure C-reactive pro-
tein (CRP; Alpha Diagnostic, San Antonio, TX, USA).
Histopathology
Synovial histopathology was evaluated in hematoxylin-
eosin (H-E) stained sections by two blinded observers,
according to the Krenn scale, as previously described
[25]. Briefly, lining hyperplasia, fibrovascular alterations
at the interstitium, and the tissue infiltration were inde-
pendently evaluated using 0 to 3-point subscales, where
0 indicates absence, 1 mild, 2 intermediate and 3 strong.
The total score was obtained from the sum of partial
grades with a maximum total score of 9 [26].
Multinucleated cell counting was performed in H-E
sections by direct analysis of 10 randomly chosen micro-
scopic fields, where lining and sublining layers were
identifiable by the observer at 20x magnification.
In order to evaluate the invasiveness of the synovium at
the posterior bone-pannus interface region, we quantified
the extent of the contact surface between the pannus and
bone/calcified cartilage, and the area of invasive pannus
in contact with bone in H-E sections of femoral condyles.
The microphotographs of the posterior bone-pannus
interface region at 40x magnification of each rabbit were
analysed. All samples were positioned in the same plane
in order to assess a similar area in each measurement.
For contact surface, the length of the boundary line
between the pannus and bone/calcified cartilage tissue
was measured. For the quantification of the invasive area,
each tissue (bone, synovial membrane or cartilage) was
identified by a distinctive color and then the area of each
color was measured. The number of cathepsin K-positive
osteoclasts was assessed in the same localization in order
to estimate active bone resorption, and was expressed as
positive cells per area. The assessment of these para-
meters was carried out with Image-Pro Plus software
(version 4.5 for Windows, Media Cybernetics, Inc, Silver
Spring, MD, USA).
Immunohistochemistry
In the synovial membrane, we identified macrophages
using a monoclonal anti-rabbit macrophage antibody
(RAM11; Dako, Glostrup, Denmark), according to proto-
col [27]. The antibody was detected with a biotinylated
goat anti-mouse IgG (1:200; Amersham, Arlington
Heights, IL, USA) visualized with a horseradish peroxi-
dase/ABComplex using 3,3diaminobenzidine tetra-
hydrochloride as the chromogen (Dako, Camarillo, CA,
USA). The tissues were counterstained with hematoxylin
and mounted in DPX medium (VWR International, Leu-
ven, Belgium). Computer-assisted analysis was performed
with Leica DMD108 Digital Micro Imaging device (Leica,
Microsystems, Inc., Buffalo Grove, IL, USA) and with
Image-Pro Plus software (version 4.5 for Windows,
Media Cybernetics, Inc, Silver Spring, MD, USA)). The
results were expressed as percentage of positive area. An
IgG isotype was used as a negative control.
CD31 immunostaining (Abcam, Cambridge, UK) was
assessed in the synovial membrane, as a marker of vascular
endothelial cells. Briefly, synovium sample slides were
scanned in the Coreo Iscan Au scanner (Ventana Medical
Systems, Tucson, AZ, USA) and then total cells, CD31-
positive cells and the entire sample area were assessed
with Virtuoso Image management software (Ventana
Medical Systems, Tucson, AZ, USA). The results were
expressed as the ratio between CD31positive cells and the
area in mm2.
Cathepsin K-positive cells were evaluated in femur
sections in order to assess bone resorption (Abcam,
Cambridge, UK). Briefly, the number of cathepsin
K-positive multinucleated cells was assessed at the
bone-pannus interface region of AIA and AIA + HFD
knees. All samples were positioned in the same plane in
order to assess a similar area in each measurement, and
the results are shown as positive staining per area.
Gene expression analysis
Total RNA was isolated from synovial membranes using
TriPure Isolation Reagent (Roche Diagnostics, Indianapo-
lis, IN, USA), according to the manufacturer´s instruc-
tions. A total of 1 µg RNA was reverse-transcribed with
the high capacity cDNA kit (Applied Biosystems, Foster
City, CA, USA) and RNA expression was quantified by
single-reporter real time PCR using the StepOnePlus™
detection system and StepOne™ software v2.2 (Applied
Biosystems). Specific oligonucleotide fluorescently labeled
primers, TaqMan FAM probe assay for TNF-a (Oc
03397715_m1) and assay-on-demand for MCP-1 were
purchased from Applied Biosystems. A pre-designed Taq-
Man FAM probe assay for GAPDH (Oc 03823402_g1,
Applied Biosystems) was also used as an endogenous con-
trol, and mRNA expression was normalized to GAPDH
RNA in each well.
Western blot analysis
Tissues were homogenized in liquid nitrogen, and total
proteins were extracted employing an extraction buffer
containing 15 mM HEPES, 10% glycerol, 0.5% NP-40,
250 mM NaCl, 1 mM EDTA, 1:1,000 phenylmethanesulfo-
nylfluoride (PMSF) and a protease inhibitor cocktail
(Sigma-Aldrich). Protein concentration was determined as
previously described [28], and subsequently, 20 μg of total
protein from each tissue was resolved on 15% acrylamide-
SDS gels. After transfer to polyvinylidene difluoride
(PVDF) membranes (Millipore, Molsheim, France) in
48 mM Tris, 39 mM glycine and 20% methanol buffer at
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20 V for 1 h at room temperature, membranes were
blocked in 5% skimmed milk in PBS-Tween 20 for 1 h at
room temperature and incubated overnight at 4°C with
anti-receptor activator of nuclear factor kappa-B ligand
(RANKL) antibodies (Peprotech, Neuilly-Sur-Seine,
France) and anti-osteoprotegerin (OPG) (R&D Systems,
Minneapolis, MN, USA) at 1/1,000 dilution each. Anti-
body binding was detected by enhanced chemolumines-
cence using peroxidase-labeled secondary antibodies, and
the results were expressed as arbitrary densitometric units
(AU). Loading control was performed on 15% acrylamide-
SDS gels by employing EZBlue gel staining reagent
(Sigma-Aldrich).
Statistical analysis
All statistical analyses were performed using SPSS ver-
sion 17.0 software for Windows (SPSS, Chicago, IL,
USA), and results were expressed as the mean ± standard
error of mean (SEM). The data from multiple groups
were compared using a Kruskal-Wallis nonparametric
test, and a pairwise comparison using the Mann-Whitney
test was applied when overall differences were identified.
P-values <0.05 were considered significant.
Results
Metabolic profile
Rabbits fed with a hyperlipemic diet (the HFD and AIA +
HFD groups) showed significant higher levels of total
serum cholesterol, HDL and triglycerides than healthy rab-
bits (P = 0.01). Likewise, the AIA + HFD group had higher
lipid levels compared with the AIA group (Figure 1B). A
decrease of rabbit weight (kg) in the HFD, AIA and AIA +
HFD groups (3.4 ± 0.19; 3.23 ± 0.22 and 3.28 ± 0.12) was
observed when compared to healthy rabbits (4.28 ± 0.06;
P < 0.002), at the time of sacrifice.
CRP levels
Levels of CRP were significantly increased in sera of AIA
and AIA + HFD groups (73.07 ± 32.58 and 124.2 ± 38.69)
in comparison with the healthy group (7.83 ± 1.28, P =
0.011 and P <0.001, respectively). In addition, CRP levels
of the AIA + HFD group were higher than the HFD group
(124.2 ± 38.69 versus 35.71 ± 13.98, P = 0.042). No signifi-
cant difference was found between the AIA and AIA +
HFD groups; however, an increased tendency is observed
in the AIA + HFD group (Figure 1C).
Increase of synovial inflammation
Histological changes of the synovial membrane were
evaluated by the Krenn synovitis score. Synovial lesions
were observed in HFD group compared with healthy rab-
bits (P = 0.005). AIA and AIA + HFD rabbits showed
much more severe synovial changes than control groups,
including lining hyperplasia, mononuclear cell infiltration
at the sublining layer and lymphoid aggregates, occasion-
ally organized into nodule-like structures (Figure 2).
These synovial features mirror those present in rheuma-
toid synovium [29].
Massive M infiltration and presence of foam cells
Although both AIA and AIA + HFD rabbits presented
the highest synovitis score, AIA + HFD synovium was
characterized by a massive infiltration of RAM11-positive
cells whose presence was greater than AIA and control
synovial membranes (P = 0.001; Figure 3E). This remark-
able feature along with the notable and consistent pre-
sence of foam cells in AIA + HFD synovium (Figures 2F
and 3F), detected by Oil Red-O staining (data not
shown), demonstrates a clear qualitative difference
between synovial membranes of similar inflammation
score grade from the AIA + HFD and AIA groups. The
presence of foam cells was detected in the sublining and
lining layers; the latter may be considered as a pathogno-
monic feature of the AIA + HFD group.
Increase of TNF-a and MCP-1 gene expression
The HFD, AIA and AIA + HFD groups showed a three-
fold increase of TNF-a gene expression levels (3.57 ±
0.73; 3.17 ± 1.25 and 2.44 ± 0.26) when compared with
healthy rabbits (1.16 ± 0.24; P = 0.005; P = 0.05 and P =
0.005). MCP-1 gene expression levels of HFD and AIA
groups were also increased when compared to the
healthy group (2.59 ± 0.54; 3.50 ± 1.42 vs. 1.04 ± 0.17;
P = 0.006; P = 0.016). AIA + HFD MCP-1 gene expres-
sion levels were lower than AIA (1.54 ± 0.22 vs. 3.50 ±
1.42; P = 0.048) (Additional file 1).
Presence of multinucleated cells resorbing adipose tissue
Macrophages arranged in crown-like structures around
adipocytes were observed in HFD, AIA and AIA + HFD
synovium (Figure 4A, B). Interestingly, we found more
frequently multinucleated cells engulfing adipocyte
structures in the AIA + HFD group (Figure 4B), and
even more progression of multinucleated cells, going
from two up to multiple nuclei (Figure 4C). The number
of multinucleated cells was significantly increased in
AIA + HFD synovium (P <0.001; Figure 4D). Circulating
synovial multinucleated cells were also observed in the
proximity of the region, some of them were cathepsin
K-positive (Figure 4E).
Increase of angiogenesis
Immunohistochemical analysis of synovial membranes
for CD31 confirmed an increased vascularization by a
higher number of vessels stained in AIA + HFD syno-
vium compared with AIA synovium. Both groups
showed by far more CD31-positive vessels than the
HFD and healthy groups (Figure 5A, E). In addition, no
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Figure 2 Histopathology of the synovial membrane. A-D, Representative sections of synovial membranes stained with hematoxylin and
eosin from healthy rabbits (A), high fat diet (HFD) rabbits (B), chronic antigen-induced arthritis (AIA) rabbits (C), and HFD+AIA rabbits (D), original
magnifications x200, scale bar = 50 µm. E, Global synovitis score, quantified as described in materials and methods. Bars show the mean and
SEM (n = 7 to 9 rabbits per group). F, Detail of the inflammatory cells observed in the AIA synovium (left side) and in the AIA + HFD synovium
(right side), original magnifications x630, scale bar = 25 µm. Inflammatory foam cells of AIA + HFD synovial membrane show an increased size
compared with inflammatory cells of AIA synovium.
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Figure 3 Immunostaining of synovial macrophages. A-D, Representative sections of synovial membranes stained with a monoclonal anti-
rabbit macrophage antibody (RAM11) from healthy rabbits (A), high fat diet (HFD) rabbits (B), chronic antigen-induced arthritis (AIA) rabbits (C)
and HFD + AIA rabbits (D), original magnifications x100, scale bar = 100 µm. E, Densitometric analysis of RAM11 staining percentage in the
synovium of each group of animals. Bars show the mean and SEM (n = 7 to 9 rabbits per group). F, Detail of the RAM11-positive cells observed
in AIA synovium (left side) and in the HFD + AIA synovial membrane (right side), original magnifications x630, scale bar = 25 µm. RAM11-
positive foam cells of increased size, some of them with three nuclei (white arrow), are present in the HFD + AIA synovium.
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difference was observed for CD31 staining between
healthy and HFD groups; however, a tendency of more
CD31 staining can be observed in HFD synovium.
Increase of active bone resorption
We estimated active bone resorption by quantifying
cathepsin K-positive osteoclasts and by determining the
Figure 4 Multinucleated cells resorbing fat tissue. A, Multinucleated cells in crown-like structure surrounding adipocytes in the synovium of
high fat diet (HFD) and chronic antigen induced arthritis (AIA) rabbits (black arrows, hematoxylin and eosin staining, original magnifications
x630, scale bar = 25 µm). B, Multinucleated foam cells resorbing adipocytes structures in the synovium of HFD + AIA rabbits (black arrows,
hematoxylin and eosin staining, original magnifications x630, scale bar = 25 µm). C, Progression of multinucleated cells presenting from two up
to multiple nuclei in the synovium of HFD + AIA rabbits. D, Quantification of multinucleated cells in the synovial membranes of AIA and HFD +
AIA rabbits. Bars show the mean and SEM (n = 7 to 9 rabbits per group). E, Circulating synovial cathepsin K-positive multinucleated cells in the
proximity of pannus region (original magnification x630, scale bar = 25 µm).
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contact surface between pannus and bone/calcified carti-
lage and the area of invasive pannus into bone. Our
results showed an increased presence of cathepsin K-
positive osteoclasts in the synovium of AIA + HFD rab-
bits compared with that of AIA rabbits (P = 0.015;
Figure 6A, B). We also observed a higher surface of
Figure 5 Angiogenesis immunostaining in the synovial membrane. A-D, Representative sections of synovial membranes stained with a
monoclonal to CD31 antibody from healthy rabbits (A), high fat diet (HFD) rabbits (B), chronic antigen induced arthritis (AIA) rabbits (C) and
HFD + AIA rabbits (D), original magnifications x100, scale bar = 100 µm. E, Semi-quantification of CD31-positive vascularization in the synovium
of each group of animals. Bars show the mean and SEM (n = 7 to 9 rabbits per group).
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Figure 6 Bone active resorption. A and B, Representative sections of the bone-pannus interface region with cathepsin K-positive cells shows
bone resorbing activity in chronic antigen-induced arthritis (AIA) rabbits (A) and HFD + AIA rabbits (B), original magnification x200, scale bar =
50 µm. C, Illustration of the region of interest evaluated in each femoral condyle at the posterior bone-pannus interface region. Contact surface
and invasive areas were analysed in hematoxylin and eosin (H-E) stained sections and then photographed in chronic antigen-induced arthritis
(AIA) rabbits (upper sections) and HFD + AIA rabbits (lower sections) (left side: H-E stained sections, right side: photographed sections, original
magnification x400, scale bar = 100 µm). D, Densitometric analysis of cathepsin K-positive staining in the synovium of both groups of animals.
Bars show the mean and SEM (n = 7 to 9 rabbits per group). E and F, Densitometric analysis of contact surface and invasive areas of AIA and
HFD + AIA rabbits. White bars correspond to AIA group and black bars to AIA + HFD group; both show the mean and SEM (n = 7 to 9 rabbits
per group).
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bone resorbing pannus in AIA + HFD than in AIA rab-
bits (Figure 6C, F). We selected the posterior pannus-
bone area as the region of interest to be measured
because osteoclast differentiation from macrophages and
activation within the aggressive pannus and subsequent
subchondral bone invasion occur in this interface.
Increase of RANKL protein levels
Both RANKL and OPG are expressed in cartilage, bone
and synovium, as previously described [30]. RANKL
expression in the HFD group was increased in all tissues
when compared to the healthy group (2.49 ± 0.29 vs.
0.99 ± 0.18, P = 0.001 in cartilage; 4.10 ± 0.46 vs. 2.26 ±
0.34, P = 0.021 in bone; and 7.06 ± 1.01 vs. 3.04 ± 0.34,
P = 0.015 in synovium). RANKL expression levels in
both AIA and AIA + HFD groups were highly increased
in all tissues when compared with the controls, healthy
and HFD groups. Specifically in the synovium, AIA and
AIA + HFD groups showed similar levels of RANKL pro-
tein expression (24.79 ± 2.23 and 24.63 ± 2.05) and were
significantly higher compared with their controls, healthy
and HFD groups (3.04 ± 0.34, P <0.001 and 7.06 ± 1.01,
P <0.001, respectively) (Additional file 2).
Discussion
This is the first in vivo study that demonstrates the harm-
ful effect of hypercholesterolemia on the severity of
chronic arthritis. Indeed, we characterized a novel model
of chronic arthritis aggravated by hypercholesterolemia,
which is driven by foam M with an aggressive phenotype.
These M markedly damaged synovial membrane, calci-
fied cartilage, juxta-articular bone and fatty tissue, and
increased angiogenesis was also evidenced in the synovial
membrane of our experimental animals. Likewise, reduced
total cholesterol and HDL levels, as well as increased low-
density lipoprotein (LDL)/vLDL, IL-6, sRANKL and CCL5
circulating levels mirroring RA patients was observed in
the K/BxAg7 mice, a novel animal model of erosive arthri-
tis followed by prominent aortic atherosclerosis. Remark-
ably, etanercept administration reduced arthritis and
atherosclerosis development in these mice [31].
We found a modest, although evident, increase of syno-
vial cell infiltration in non-arthritic rabbits fed with
hypercholesterolemic diet. Accordingly, an atherogenic
lipid profile characterized by high total cholesterol, trigly-
ceride and apo B levels, and low HDLc levels was more
prevalent in blood donors who later developed RA [32].
Similarly, a higher risk of moderate to severe RA was
found in patients with metabolic syndrome [33]. Recent
obesity studies have supported these findings since the
lipid profile may also be influenced by weight/body mass
index. Obesity has been associated with a modest risk for
developing RA, but the rapid increase in obesity preva-
lence may be responsible for much of the increase in RA
incidence [34]. Moreover, obesity was associated with
worse RA disease outcomes, high prevalence of comorbid-
ities and the poor therapy effect of glucocorticoids, dis-
ease-modifying antirheumatic drugs (DMARDs) and
biologic agents [35-37]. All these findings suggest that
hyperlipidemia may influence the initiation and progres-
sion of chronic inflammatory synovitis as well as indicate
the potential relevance of its pharmacology modification.
Since there are no clearly designed studies showing that
hypercholesterolemia increases chronic synovitis, investi-
gating the effects of hypolipidemic statins on the course
of RA may provide additional clues to this relationship.
Besides their well-established beneficial effects on lipid
metabolism in patients with hypercholesterolemia, cardi-
ovascular diseases and inflammatory diseases [38-40],
statins have also been shown to exert anti-inflammatory,
antioxidant, immunomodulatory and antithrombotic
effects [41]. A six-month clinical trial reported a modest
but significant clinical improvement in RA subjects trea-
ted with atorvastatin [39]. Interestingly, a recent large
population-based cohort study has shown an association
between good adherence to statin treatment and reduced
risk of developing RA [42]. Likewise, statins reduced the
risk for the development of RA between 30% and 40%,
although lipid lowering drugs other than statins were not
associated with a decreased risk [43]. Hence, statins may
be protective against development and progression of RA
in those with hyperlipidemia.
Massive infiltrates of RAM11-positive macrophages, a
major number of multinucleated cells and the presence of
foam-like cells were characteristically seen in the AIA +
HFD synovium. Activation of blood mononuclear cells as
shown by enhanced nuclear factor-kappa B (NF-B) tran-
scription binding and massive M infiltration in athero-
sclerotic plaques was previously described in the
combined model [16]. Taken together, these findings sug-
gest that the activation of peripheral monocytes could lead
to systemic inflammation producing a huge M tissue
infiltration, accounting for the synovitis aggressiveness
observed in this experimental model. In accordance, sev-
eral quantitative immunohistological studies have high-
lighted the relevance of M in driving the inflammatory
response. The number of M was increased in clinically
affected joints compared with non-affected joints [44], and
correlated well with clinical signs of disease activity,
including joint pain and swelling [18]. Of relevance, the
change in the number of sublining M has been proposed
as a sensitive biomarker to predict possible efficacy of new
anti-rheumatic treatment [45].
The high plasticity of macrophages, as shown by the
marked transformation of macrophages into foam cells,
lipid-engulfed multinucleated cells and further cathepsin
K-stained osteoclasts, was one of the major findings in
hyperlipidemic rabbits with chronic arthritis. As described
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in the adipose tissue of obese mice and humans [17,46],
macrophages were frequently observed around dead adi-
pocytes forming characteristic ‘crown-like’ structures. This
shows an exacerbated phagocytosis of dead adipocytes by
activated macrophages in the sublining of AIA + HFD rab-
bits. The increased transformation of activated macro-
phages into foam cells in the lining and sublining layers of
hyperlipemic animals with AIA occurs as a result of the
enhanced uptake by their scavenger receptors of oxidized
low density lipoproteins (oxLDL). A disruption of the tran-
scriptional equilibrium mediated by lipid sensors between
lipid metabolism and immune functions in macrophages
promotes the enhancement of pro-inflammatory signals
during their activation, and finally leads to formation of
foam cells [17]. A persistent imbalance between pro- and
anti-inflammatory mediators released by macrophages
and/or deficient clearance of apoptotic foam cells can per-
petuate chronic inflammation [47]. Indeed, macrophages
from experimental animals generated significant levels of
TNF-a gene expression and, potentially, other inflamma-
tory mediators, such as IL-6 signaling, that may have
induced C-reactive protein expression [16].
The growth of the synovial membrane was accompanied
by neovascularization, as demonstrated by the increased
CD31+ staining of blood vessels in AIA and, particularly,
in AIA + HFD synovial membranes. Activated macro-
phages promote angiogenesis by the production of angio-
genic factors, including pro-inflammatory cytokines,
growth factors and chemokines that promote endothelial
cell adhesion, receptor expression and neovascularization
[48]. Many of these molecules were not induced in adipose
tissue macrophages from C-C chemokine receptor 2
(CCR2) knockout mice fed with a high-fat diet, supporting
the importance of CCR2 in regulating recruitment of
inflammatory activated macrophages during obesity [49].
Successful treatment of RA with anti-TNF antibodies
reduced levels of pro-angiogenic factors, including vascu-
lar endothelial growth factor (VEGF), and led to normali-
zation of the vasculature. In addition, leptin has been
suggested to induce angiogenesis in endochondral ossifica-
tion [50]. These data emphasize the close links among
angiogenesis, inflammation and obesity in this disease. In
our animal model, whether hypercholesterolemia boosts
angiogenesis in the synovium of arthritic rabbits remains
to be established and ongoing research is being carried out
in this regard.
The phenotype transformation of macrophages to cathe-
psin K-stained osteoclasts observed in AIA and, particu-
larly, in AIA rabbits fed with a hyperlipemic diet
remarkably resembles the development of osteoclasts from
monocytes/macrophage precursor cells, one of the unique
characteristic of RA [7]. Cathepsin K is the major protease
of osteoclasts responsible for bone resorption and its
specific degradation product, C-terminal telopeptide of
collagen type I (CTX-I), has been extensively used as a
surrogate measure of bone resorption [7,10,51-53]. Thus,
the high active bone resorption found in AIA + HFD
synovial membranes shows the influence of hyperlipidemia
on bone metabolism. In fact, human macrophage foam
cells produce CTX-I fragments in atherosclerotic plaques
[19,20,22,23,53,54]. Multiple parameters of bone quality
were altered by a hypercholesterolemic diet in mice,
including bone mineral density (BMD) bone volume frac-
tion, number of trabeculae and trabecular spacing, along
with changes in the mechanical properties of the bone and
an increase in bone resident osteoclasts [24]. Although
synovitis score and the expression levels of RANKL, OPG
and TNF-a were similar in AIA and AIA + HFD groups,
bone resorption activity was remarkably increased in
AIA + HFD rabbits suggesting a greater RANKL activity
or efficiency in the presence of high LDL levels. It has
recently been described that LDL deficiency causes
impaired osteoclastogenesis with a subsequent decrease in
bone resorption parameters and increased bone mass in
mice due to a defect in osteoclastic cell-cell fusion [55]. In
addition, Wnt-mediated signals might be altered in hyper-
lipidemia and, subsequently, affect bone resorption [56].
Thus, hypercholesterolemia may directly disrupt bone
homeostasis.
Conclusions
These findings provide a valuable piece of information
about the hypercholesterolemia pathogenicity at the
synovial membrane and cartilage-pannus junction. The
hyperlipidemia-boosted systemic inflammation markedly
damages articular tissues by macrophage massive infil-
tration and transformation to foam cells and active
osteoclasts. In this context, M accumulation at the site
of inflammation may be a direct response to the abnor-
mal fat metabolism caused by the increasing adiposity.
Therefore, this experimental model shows that hyperch-
olesterolemia markedly increments joint tissue damage
in chronic arthritis, demonstrating a key role of synovial
macrophages in this process, as well as their potential as
a suitable target for successful RA therapy.
Additional material
Additional file 1: High fat diet (HFD) and antigen induced arthritis
(AIA) interventions increase TNF-a (A) and MCP-1 (B) gene
expression in the synovium. Gene expression was examined by real
time PCR and results are expressed as fold induction. Bars show the
mean and SEM (n = 7 to 9 rabbits per group).
Additional file 2: RANKL and OPG protein expression. A, C and E,
Densitometric analysis of receptor activator nuclear kappa B ligand
(RANKL) and osteoprotegerin (OPG) protein expression in cartilage (A),
subchondral bone (C) and synovium (E). Bars show the mean and SEM
(n = 7 to 9 rabbits per group). B, D and F, Representative Western blot
images for RANKL and OPG detection in cartilage (B), subchondral bone
(C) and synovium (F). EZ Blue-stained gels used as protein loading
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controls are also shown for healthy rabbits, high fat diet (HFD) rabbits,
chronic antigen induced arthritis (AIA) rabbits and HFD + AIA rabbits.
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